Description

Dexrazoxane CAS NO 24584-09-6 is a cardioprotective agent and topoisomerase II inhibitor used as a pharmaceutical active ingredient. Its primary commercial value lies in its critical role in mitigating the cardiotoxic side effects associated with certain chemotherapeutic agents, particularly anthracyclines like doxorubicin. This compound is essential for manufacturers in the pharmaceutical industry developing and producing specialized oncology medications and supportive care formulations.

Application

• Oncological Supportive Care: Primary use as a cardioprotectant to reduce the incidence and severity of cardiomyopathy induced by anthracycline chemotherapy.
• Pharmaceutical Formulation: Serves as the active pharmaceutical ingredient (API) in injectable drug products designed for adjunctive therapy in cancer treatment.
• Clinical Research: Utilized in preclinical and clinical studies investigating cardioprotective strategies and mechanisms of action against drug-induced tissue damage.
• Drug Development: A key intermediate or reference standard in the R&D of new chemoprotective agents and combination therapies.
• Topoisomerase II Inhibition: Employed in biochemical research for its ability to inhibit topoisomerase II, useful in studying DNA replication and repair processes.
• Veterinary Medicine: Potential application in veterinary oncology for managing chemotherapy side effects in animals.

Basic Information

Product Name	Dexrazoxane
CAS No.	24584-09-6
Molecular Formula	C11H16N4O4
Molecular Weight	268.27 g/mol
Synonyms	(+)-1,2-Bis(3,5-dioxopiperazinyl)propane; ICRF-187; ADR-529; Cardioxane; Razoxane enantiomer; Dexrazoxane Hydrochloride (salt form); (S)-(+)-Razoxane; EINECS 246-344-1
EINECS	246-344-1

Quality Control

Our Dexrazoxane is manufactured and tested under a strict quality management system. It meets high-purity standards suitable for pharmaceutical application development. Comprehensive testing includes identity, assay, impurity profiling, and residual solvent analysis. A Certificate of Analysis (COA) documenting compliance with agreed specifications is provided with each batch. We support compliance with ICH guidelines for impurities and can supply material referenced to pharmacopeial standards (e.g., USP) upon request.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at controlled room temperature (15-25°C) or as specified. Due to its hygroscopic nature, the container must be kept tightly sealed in a dry environment to prevent moisture absorption. Keep away from incompatible materials.

Specification

Item	Specification
Appearance	White to off-white crystalline powder
Identification (IR)	Conforms to reference spectrum
Identification (HPLC)	Retention time corresponds to reference standard
Assay (HPLC)	98.0% - 102.0% (on anhydrous basis)
Water Content (KF)	≤ 1.0%
Residue on Ignition	≤ 0.1%
Heavy Metals	≤ 20 ppm
Related Substances (HPLC)	Individual impurity ≤ 0.5%; Total impurities ≤ 1.5%
Optical Rotation	[α]20/D: +22° to +28° (c=1 in water)

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.